About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Pfizer Just Invested $25 million In This Biotech

Caribou Biosciences stock price

Shares of Caribou Biosciences (NASDAQ: CRBU) were up 45% yesterday after Pfizer (NYSE: PFE) made a $25 million equity investment. On Thursday, the company said Pfizer bought almost 4.7 million shares of CRBU on June 29 at $5.33 a share. The purchase was part of a securities purchase agreement that closed on June 30. The company said it will use the proceeds to finance the development of its pipeline.

The market reacted extremely positively to the news, with the stock paring back most of its YTD losses, now just down 5.4%. The stock caught the attention of retail and professional participants as volume surged to record heights yesterday. The stock traded 83.4 million shares, compared to its 2.14 million average volume.

Caribou Biosciences is a clinical-stage biopharmaceutical company. The company engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally.

Caribou stock chart
As a result of the fundamentally changing catalyst, shares of CRBU broke the higher time frame downtrend yesterday. The stock had been in a lengthy downtrend and, in recent months, began to consolidate sideways, indicating less selling pressure and the potential for a trend reversal.

Caribou currently has 61.3 million outstanding shares, 55.5 million free float, and a market cap of $364 million.

Analysts See Potential

Being a clinical-stage biotech with a small market cap, Caribou doesn't boast extensive analyst coverage. However, of the four analysts that cover the company, CRBU has a consensus analyst rating of Buy. More impressively, the stock has a consensus analyst price target of $27.60, predicting a 364% potential upside. Among the four analysts, the stock has a higher prediction of $37 and a low prediction of $19.

Caribou's Pipeline

caribous pipeline do revenue chart

Per the company's website, their pipeline currently includes two lead candidates: CB-010 and CB-011, both currently in phase 1 trials.

CB-010 is the company's lead clinical-stage program, an allogenic anti-CD19 CAR-T cell therapy. It treats patients with relapsed or refractory B cell non-Hodgkin lymphoma.

CB-011 is the company's second clinical-stage program and is an allogeneic anti-BCMA CAR-T cell therapy used to treat patients with relapsed or refractory multiple myeloma.

It Might Be Worth Taking A Closer Look

Caribou's pipeline also includes CB-012, an anti-CD371 CAR-T therapy for relapsed/refractory acute myeloid leukemia, and CB-020, a CAR-NK therapy for solid tumors. With the last reported $291 million in cash, Caribou can fund operations until 2025. The move by Pfizer certainly shows confidence in Caribou's management team and pipeline. It might even signal a potential buyout down the road by Pfizer.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.